Generic drug stocks slumped following President Trump's July 22 announcement of plans to impose tariffs on generic drugs starting in August 2028. On July 24, the Trump administration implemented new tariffs of 10% and 12.5% on 60 trading partners as temporary duties expired. These policy moves directly impacted market valuations for companies within the generic pharmaceutical sector.
